Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

Abstract

Background Tuberous sclerosis complex is a genetic disorder leading to constitutive activation of mammalian target of rapamycin (mTOR) and growth of benign tumours in several organs. In the brain, growth of subependymal giant cell astrocytomas can cause life-threatening symptoms--eg, hydrocephalus, requiring surgery. In an open-label, phase 1/2 study, the mTOR inhibitor everolimus substantially and significantly reduced the volume of subependymal giant cell astrocytomas. We assessed the efficacy and safety of everolimus in patients with subependymal giant cell astrocytomas associated with tuberous sclerosis complex.Methods In this double-blind, placebo-controlled, phase 3 trial, patients (aged 0-65 years) in 24 centres in Australia, Belgium, Canada, Germany, the UK, Italy, the Netherlands, Poland, Russian Federation, and the USA were randomly assigned, with an interactive internet-response system, in a 2:1 ratio to oral everolimus 4·5 mg/m(2) per day (titrated to achieve blood trough concentrations of 5-15 ng/mL) or placebo. Eligible patients had a definite diagnosis of tuberous sclerosis complex and at least one lesion with a diameter of 1 cm or greater, and either serial growth of a subependymal giant cell astrocytoma, a new lesion of 1 cm or greater, or new or worsening hydrocephalus. The primary endpoint was the proportion of patients with confirmed response--ie, reduction in target volume of 50% or greater relative to baseline in subependymal giant cell astrocytomas. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00789828.Findings 117 patients were randomly assigned to everolimus (n=78) or placebo (n=39). 27 (35%) patients in the everolimus group had at least 50% reduction in the volume of subependymal giant cell astrocytomas versus none in the placebo group (difference 35%, 95% CI 15-52; one-sided exact Cochran-Mantel-Haenszel test, p<0·0001). Adverse events were mostly grade 1 or 2; no patients discontinued treatment because of adverse events. The most common adverse events were mouth ulceration (25 [32%] in the everolimus group vs two [5%] in the placebo group), stomatitis (24 [31%] vs eight [21%]), convulsion (18 [23%] vs ten [26%]), and pyrexia (17 [22%] vs six [15%]).Interpretation These results support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis. Additionally, everolimus might represent a disease-modifying treatment for other aspects of tuberous sclerosis.Funding Novartis Pharmaceuticals.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(12)61134-9

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Cited by

See all 794

Metadata

Authors
Franz, D. N., Belousova, E., Sparagana, S., Bebin, E. M., Frost, M., Kuperman, R., Witt, O., Kohrman, M. H., Flamini, J. R., Wu, J. Y., Curatolo, P., de Vries, P. J., Whittemore, V. H., Thiele, E. A., Ford, J. P., Shah, G., Cauwel, H., Lebwohl, D., Sahmoud, T., & Jozwiak, S.
Affiliations
  • Cincinnati Children's Hospital Medical Center (US)
  • Texas Scottish Rite Hospital for Children (US)
  • University of Alabama (US)
  • Minnesota Epilepsy Group (US)
  • UCSF Benioff Children's Hospital (US)
  • German Cancer Research Center (DE)
  • University of Chicago (US)
  • Children's Healthcare of Atlanta (US)
  • University of California, Los Angeles (US)
  • University of Rome Tor Vergata (IT)
  • National Institutes of Health (US)
  • Massachusetts General Hospital (US)
  • Novartis (United States) (US)
Corresponding author
Franz, David Neal
Venue
The Lancet
Publisher
Elsevier BV
Published
2013-01
Volume
381
Issue
9861
Pages
125-132
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2139802897
Cited by
794
References
33
Citations by year
2026: 29 · 2025: 43 · 2024: 26 · 2023: 56 · 2022: 48 · 2021: 63 · 2020: 45 · 2019: 48 · 2018: 56 · 2017: 65 · 2016: 83 · 2015: 88 · 2014: 79 · 2013: 60
FWCI
49.35
Type
journal article
Language
en
Update notices
erratum (2013-01-12)
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
Funders
Novartis
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoidosis and Beryllium Toxicity Research
Keywords
everolimus, subependymal giant cell astrocytoma, tuberous sclerosis complex, mTOR inhibitors, hydrocephalus, tumor shrinkage, drug safety, adverse events, pediatric brain tumors, targeted therapy, treatment discontinuation
MeSH terms
Everolimus, Adolescent, Adult, Astrocytoma, Child, Child, Preschool, Double-Blind Method, Female, Fever, Humans, Infant, Male, Seizures, Stomatitis, Tuberous Sclerosis, Treatment Outcome, Oral Ulcer, Sirolimus, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(12)61134-9
The paper
Franz, D. N., Belousova, E., Sparagana, S., Bebin, E. M., Frost, M., Kuperman, R., Witt, O., Kohrman, M. H., Flamini, J. R., Wu, J. Y., Curatolo, P., de Vries, P. J., Whittemore, V. H., Thiele, E. A., Ford, J. P., Shah, G., Cauwel, H., Lebwohl, D., Sahmoud, T., & Jozwiak, S. (2013). Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(12)61134-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.